The Albany Medical College 
of Union University 
Albany New York 12208 
OCPAMTMCNT or MICMOaiOLOOV ANO IMMUNOLOOT 
TMC MCll. HALLMAM li«0<Ai. AfMAACM 
iSIti 4AS-SIU 
March 20, 1981 
Dr. Elizabeth Mllewskl 
Office of Recombinant DNA Activities 
Building 31, Room AA52 
National Institutes of Health 
Bethesda, Maryland 20205 
Dear Dr. Mllewskl: 
Dr. Donald Dean, director of the Bacillus Genetic Stock Center, has 
recently requested that the NIH Guidelines on utilization of Bacillus 
subtllls In recombinant DNA experiments be eased. The suggested changes 
on the use of asporogenlc mutants, and redefining the physical containment 
levels for cloning DNA from CDC class 1 organisms and from other Bacilli 
Into sporogenlc subtllls strains seem to make a lot of sense. I would 
like to support Dr. Dean's request In the strongest terms. 
Sincerely yours, 
Harry W. Taber, Ph.D. 
Professor of Microbiology 
and Immunology 
HWTikc 
( 569 ] 
